Stockscreener 앱 받기
8.10
4.38%
0.34
시간 외 거래:
8.10
전일 마감가:
$7.76
열려 있는:
$7.86
하루 거래량:
244.19K
Relative Volume:
2.10
시가총액:
$75.72M
수익:
$24.99M
순이익/손실:
$-108.83M
주가수익비율:
-0.539
EPS:
-15.0286
순현금흐름:
$-91.62M
1주 성능:
+10.81%
1개월 성능:
+5.47%
6개월 성능:
+7.64%
1년 성능:
-24.70%
1일 변동 폭
$7.79
$8.33
1주일 범위
$7.31
$8.3694
52주 변동 폭
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
명칭
Adicet Bio Inc
전화
617-482-2333
주소
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
8.10 | 75.81M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-30 | 재개 | Guggenheim | Buy |
| 2024-09-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-06-27 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-03-31 | 개시 | SMBC Nikko | Outperform |
| 2022-03-08 | 개시 | Truist | Buy |
| 2022-03-04 | 개시 | Jefferies | Buy |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2021-04-23 | 개시 | H.C. Wainwright | Buy |
| 2021-04-14 | 개시 | Canaccord Genuity | Buy |
| 2021-04-08 | 개시 | Guggenheim | Buy |
| 2020-11-04 | 개시 | B. Riley Securities | Buy |
| 2020-10-27 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-16 | 개시 | Wedbush | Outperform |
모두보기
Adicet Bio Inc 주식(ACET)의 최신 뉴스
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Adicet Bio Inc. (ACET) Q1 2026 Earnings: Narrowed Loss Beats Street on Cost Discipline, Pipeline ProgressEBITDA Estimate Trend - newsline.com
Adicet Bio teases autoimmune data catalysts, PSMA plans at Jefferies conference - MSN
ACET Q1 2026 Earnings: Better-than-Expected Losses Lift SharesAdjusted Earnings Analysis - newsline.com
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
BPAS - FinancialContent
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference - sharewise.com
Adicet Bio (ACET) Slips Nearly 6% as Shares Test Key Support LevelsLong Short Pair - newsline.com
Adicet Bio Inc. (ACET) Surges 7.75% as Bullish Momentum BuildsDividend Arbitrage - The Legal Advocate
Are medical stocks lagging Adicet Bio (ACET) this year? - MSN
ACET Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 7.75% Share LiftProfit Inflection Point - newsline.com
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
Adicet Bio Inc. (ACET) Rises 1.65% as Biotech Sector Shows Mixed SignalsVolume Breakout Ideas - newsline.com
Adicet Bio (ACET) Edges Higher: Modest Gain Amid Key Support and Resistance LevelsBollinger Band - The Legal Advocate
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade - Yahoo Finance
Adicet Bio Shares Halted Ahead of Data Readout That May Steer ACET - Bez Kabli
Adicet Bio (ACET) Shows Resilient Move, Testing Key Resistance After 3.4% GainVerified Analyst Reports - Newser
ACET Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponsePreliminary Results - newsline.com
Adicet Bio (ACET) Q1 2026 Earnings: EPS $-1.88 Beats EstimatesRevenue Beat Analysis - Newser
Adicet Bio, Inc. 2025 10-K/A Annual Report: Controls, Procedures & Internal Control Certifications - Minichart
Adicet Bio (ACET) updates 10-K to confirm effective 2025 controls - Stock Titan
ACET Stock Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (ACET) Falls -2.34% — Watching $7.12 Support 2026-05-18Total Put Call - newsline.com
Adicet Bio (ACET) price target decreased by 34.28% to 35.53 - MSN
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Adicet Bio CEO to discuss cell therapies at Jefferies health conference - Stock Titan
JonesTrading Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $20 - Moomoo
Press Release Service: Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio (NASDAQ: ACET) cuts Q1 2026 loss while advancing prula-cel and ADI-212 pipeline - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - New Castle News
Lupus, arthritis and prostate cancer: new cell trials planned by Adicet Bio - Stock Titan
ACET Stock Price, Quote & Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Jefferies Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $19 - Moomoo
Jefferies initiates Adicet Bio stock with buy rating, $19 target By Investing.com - Investing.com Australia
Jefferies initiates Adicet Bio stock with buy rating, $19 target - Investing.com India
Johnson & Johnson Sells 341,693 Shares of Adicet Bio, Inc. $ACET - MarketBeat
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adicet Bio (NASDAQ:ACET) Rating Increased to Sell at Wall Street Zen - MarketBeat
Adicet Bio Inc (ACET) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adicet Bio Inc 주식 (ACET) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 19 '26 |
Buy |
7.21 |
74,268 |
535,472 |
1,107,873 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 18 '26 |
Buy |
7.04 |
74,577 |
525,022 |
1,033,605 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 08 '26 |
Sale |
6.42 |
72,939 |
468,082 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 07 '26 |
Sale |
6.52 |
31,719 |
206,765 |
32,523 |
2.60%
0.94%
자본화:
|
볼륨(24시간):